logo
Propel Software Survey Reveals Key Insights for Product Operations in Discrete Manufacturing

Propel Software Survey Reveals Key Insights for Product Operations in Discrete Manufacturing

Business Wire16-07-2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Propel Software, creator of the first product value management (PVM) platform that transforms how businesses create, market, sell, and service products, today released findings from its State of Product Innovation 2025: AI Adoption and Collaboration Trends Across Four Industries research. The survey of 800 U.S. employees across industrial equipment, medical device, high tech and consumer goods industries, commissioned by Propel Software and conducted by Talker Research, found that lack of collaboration and disparate systems are negatively impacting product operations, including sourcing and production decisions, product quality, and speed to market.
Propel Software survey reveals key insights for product operations in discrete manufacturing
Share
The survey found that collaboration is a challenge for all industries and product roles, with 49% of respondents saying their product teams (e.g. engineering, quality, supply chain) don't effectively collaborate among their own departments. Technology barriers were the main culprit, such as not having a common system or integrated systems that limit or prevent collaboration (55%). If they could address the collaboration issue, 23% believe it would mainly benefit product quality; 21% said it would allow for better production decisions.
Collaboration between product and commercial teams was also an area of concern with 43% of respondents reporting ineffective collaboration between the two key stakeholder groups. As with the product team, technology barriers such as not having a common system or integrated systems that limit or prevent collaboration (58%) were top challenges. If they could address collaboration challenges, respondents believe it would improve product quality and allow products to get to market faster.
Lack of collaboration business impacts
Survey respondents across departments weighed in on top product innovation challenges including development, launch, and sales processes:
Product Management
Scoping the time and effort to develop new products or enhancements (24%)
Managing product changes (22%)
Coordinating across teams (15%)
Marketing
Having easier access to accurate and up-to-date product data (40%)
Tools to compare product variants or configurations (35%)
Better collaboration with product and engineering teams (33%)
Sales
Quick access to accurate, up-to-date product information (42%)
Faster responses to customer product questions (42%)
Improved coordination with product and marketing teams (41%)
Additional role-specific findings:
Quality/Regulatory: The biggest challenges related to system validation or compliance readiness respondents face are maintaining ongoing system compliance after upgrades or changes (34%), managing validation documentation and audit trails (22%) and keeping up with evolving regulations (17%).
Supply Chain: When a key part becomes unavailable or is delayed, respondents currently search for alternatives manually (37%), escalate to the procurement or supplier manager (36%) or use ERP or sourcing platforms to find alternates (28%).
Service/Support: Only 25% say they're always aware of changes to a product before interaction with customers or assets.
'Siloed departments and disconnected software solutions are no match for today's fast-paced market demands, and the urgency to innovate has never been greater,' said Ross Meyercord, CEO of Propel Software. 'With a secure data foundation and AI embedded into the core of a manufacturer's data architecture, companies can scale AI confidently to enhance collaboration, drive efficiency and bolster product operations. To minimize risk and maintain control, manufacturers should prioritize cloud-native, SaaS-based solutions that consolidate operations onto a single platform.'
AI presents opportunities and apprehension
Sixty-five percent of respondents are using AI in their product operations and seeing success. However, respondents also reported hesitancy to adopt AI within the systems they use for product-related operations because of data privacy or IP leakage concerns (34%), high cost/low ROI (28%) and a lack of trust in AI recommendations (27%). Other key AI usage statistics reported include:
Respondents actively using AI and expanding investment: high tech (51%), industrial equipment (32%), consumer goods (26%) and medical devices (24%)
Piloting or experimenting with AI in limited areas: consumer goods (34%), medical devices (33%), industrial equipment (32%) and high tech (31%)
Those respondents actively using AI justify their AI investments through productivity gain (52%), ability to achieve a competitive advantage (50%), technology consolidation (35%), ability to reallocate resources (32%), direct expense reduction (28%) and ability to reduce headcount (23%).
The State of Product Innovation 2025: AI Adoption and Collaboration Trends Across Four Industries survey responses were collected from 800 product management, design engineering, quality/regulatory, supply chain, sales, product marketing, service/support, and IT staff members in the industrial equipment, medical devices, high tech, and consumer goods industries in the U.S.
Static and animated survey infographics are available for review here.
About Propel Software
Propel helps product companies grow revenue and increase business value. Our product value management platform connects commercial and product teams to optimize decision making, drive process efficiencies, and engage customers with compelling products and experiences. Propel has a proven track record of improving product quality, speeding time to revenue and profit, and improving customer satisfaction. Recognized as one of America's fastest growing private companies on the Inc 5000, Propel is also a Deloitte Technology Fast 500 winner, and one of Fortune America's Most Innovative Companies. Built on Salesforce, Propel drives product success for hyper growth startups, corporate pioneers, and Fortune 500 leaders in the high tech, medtech and consumer goods industries. For more information, visit propelsoftware.com and follow us on LinkedIn.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia

Business Wire

time16 minutes ago

  • Business Wire

Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

Business Wire

timean hour ago

  • Business Wire

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

LEIDEN, Netherlands--(BUSINESS WIRE)-- Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros, and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' Share The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' said Stefano Portolano, Chief Executive Officer at Azafaros. 'We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy.' About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.

GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year

Business Wire

time4 hours ago

  • Business Wire

GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year

HONG KONG--(BUSINESS WIRE)-- Guotai Junan International Holdings Limited ('GTJAI' or the 'Company', stock code: a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions, it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved 'carbon neutrality' at the operational level, demonstrating the Company's leading practice and commitment to green operation. The carbon credits come from 'Guoluo Grassland Sustainable Management Project' located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilization construction, and to effectively respond to the challenges of climate change. The project is also the first grassland carbon project in China receiving both VCS certification and the Climate, Community and Biodiversity Standards (CCB) - CCB-Biodiversity Gold Level certification. In recent years, GTJAI has been continuously reducing its operational carbon footprint through systematic energy saving and emission reduction initiatives, which is the core support for the achievement of 'carbon neutrality', including vigorously implementing energy-saving renovation of office space, deepening digitalization and paperless transformation, and implementing stringent waste management (100% safe recycling of hazardous waste by 2024). Solid internal emission reduction efforts, combined with carbon offsetting through high-quality carbon credits, enabled the Company to achieve 'carbon neutrality' at the operational level. Adhering to the core philosophy of 'finance for the country, finance for the people, finance for the good', GTJAI has always placed sustainable development at the core of its corporate strategy. The Company is committed to supporting the real economy through financial services while facilitating the green transformation of its corporate clients. In 2024, the Company successfully completed 90 sustainable finance projects covering green bonds, sustainable bonds and green sector IPOs with a total issuance volume of HK$179.8 billion, significantly broadening the financing pipeline for the green industry. Meanwhile, the private equity sector is actively engaged in the sustainability sector, with more than half of its investments focusing on ESG-related industries. Looking ahead, GTJAI will deepen the level of ESG governance, fully integrate ESG factors into its operations and management processes, further leverage its professional strengths and enhance the level of green financial services capabilities. Through innovative products and services, GTJAI will proactively contribute to the realization of the country's 'dual carbon' goal and promote the high-quality development of the economy and society. About GTJAI Guotai Junan International ('GTJAI', Stock Code: a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI's business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned 'Baa2' and 'BBB+' long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG 'A' rating, Wind ESG 'A' rating and SynTao Green Finance 'A' rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China's capital markets. For more information about GTJAI, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store